摘要
心力衰竭(心衰)因其复杂的发病机制和缺乏有效的治疗方案成为目前医学领域的研究难点。NO-sGCcGMP通路是一条与心血管疾病密切相关的、高度保守的信号通路。维立西呱是心衰治疗领域针对NO-sGCcGMP通路首次取得阳性结果的药物,为心衰的临床治疗带来新角度、新思路。本文将简述基于该途径研发的可溶性鸟苷酸环化酶激动剂维立西呱在心衰领域的研究进展,对维立西呱治疗心衰的作用机制、临床前研究、临床研究以及在我国的进展情况进行综述,以期为临床合理用药提供帮助。
Heart failure,as a common,incurable and life-threatening condition,is a fortress we have yet to conquer.The NO-sGC-cGMP pathway plays an important role in endothelial function and myocardial energy metabolism.Vericiguat is the first drug in the field of heart failure that has achieved positive results for this pathway,providing new perspectives and methods for clinical treatment of heart failure.In this paper,the research progress of soluble guanylate cyclase agonist vericiguat in the field of heart failure was reviewed,including the mechanism of action of vericiguat in the treatment of heart failure,preclinical studies,clinical studies and its progress in China,with the aim for rational clinical administration of vericiguat.
作者
佘林聪
方业贤
王家欣
冯艳
陈江红
张薇
SHE Lin-cong;FANG Ye-xian;WANG Jia-xin;FENG Yan;CHEN Jiang-hong;ZHANG Wei(Department of Cardiology,Second Affiliated Hospital,Air Force Medical University,Xi’an 710038,Shaanxi,China)
出处
《心脏杂志》
CAS
2024年第2期230-235,共6页
Chinese Heart Journal
基金
社会人才基金资助计划项目(2021SHRC025)。
